You are here: Home
Sunday, 25.02.2018

59th Annual Congress of the SCNP

We are happy to announce that our 59th Annual Congress will take place in Aarhus, Denmark, from April 11th-13th, 2018.

Sign-up and abstract submission is open

REGISTRATION

ABSTRACT SUBMISSION

Program

PRE-MEETING EVENT

WEDNESDAY, April 11th, 2018

13.00-19.00 SCNP-CINP EDUCATIONAL WORKSHOP
CAREER WORKSHOIP
(seats limited to 30, priority given to participants in the Congress)
HOW TO PROTECT AND COMMERCIALISE YOUR RESEARCH 
Workshop speakers & discussants
Jos Prickaerts (Maastricht, Netherlands)
Gregers Wegener (Aarhus, Denmark) Simon Glerup Pedersen (Aarhus, Denmark)

 THURSDAY, APRIL 12th, 2018

09.00- REGISTRATION OPENS 
09.00-10.00 SCNP GENERAL ASSEMBLY 
10.00-10.05 SCNP 2017 Opening
President’s Welcome
Gregers Wegener (Aarhus, Denmark) 
10.05-10.50 OPENING LECTURE
SCNP 2016 Opening Lecture
Moderator: Gregers Wegener (Aarhus, Denmark)
Predicting treatment response in depression  
Thomas Frodl (Magdeburg, Germany)
10.50-11.00 STRETCHING LEGS BREAK 
11.00-13.00 PLENARY SESSION
Drugs in the pipeline
Moderators: Ole A. Andreassen (Oslo, Norway), Sophie Erhardt (Stockholm, Sweden)
Title to be announced
Connie Sanchez (Alkermes. Inc., USA)
New Strategies in treatment of psychosis
Speaker to be confirmed
Inhibitors of Phosphodiesterase in psychiatric disease  
Jos Prickaerts (Maastricht, Netherlands)
13.00-13.45 LUNCH 
13.45-15.15 SCNP YOUNG SCIENTIST SYMPOSIUM
Moderators: Gregers Wegener (Aarhus, Denmark) & Ole A. Andreassen (Oslo, Norway)
Speakers to be announced (based on competition) 
15.15-15.45 COFFEE BREAK 
15.45-16.30 SCNP LECTURE
Moderator: Páll Matthíasson (Reykjavik, Iceland)
How can we learn from predrug trials without replication?
Malcolm McLeod, (Edinburgh, UK) 
16.30-17.15 SCNP LECTURE
Moderator: Olli Kampman (Tampere, Finland)
Efficacy of SSRIs in depression revisited
Fredrik Hieronymus/Elias Eriksson (Gothenburg, Sweden) 
17.15-18.45 POSTER SESSION
Refreshments 
19.45- SCNP 2017 Dinner
Restaurant det glade vanvid, Aarhus

 FRIDAY, APRIL 13th, 2018

09.00-09.45 SCNP LECTURE
Moderator: Sophie Erhardt (Stockholm, Sweden)
The role of Glutamatergic antidepressants in depression
Gregers Wegener (Aarhus, DK) 
09.45-10.15 COFFEE BREAK 
10.15-11.45 PLENARY SESSION
Psychosis, implications for diagnosis and intervention
Moderators: Ole Andreassen (Oslo) & Bo Söderpalm (Gothenburg, Sweden)
PANNS-6: A new rapid rating scale in psychosis
Søren Dinesen Østergaard (Aarhus, Denmark)
Effectiveness of Antipsychotic Treatments in Schizophrenia.
Erik Johnsen (Oslo, Norway)
What can genetics be used for as diagnostics in a clinical setting in psychosis?
Markku Lähteenvuo (Helsinki, Finland)
11.45-13.15 PLENARY SESSION
Psychopharmacology in child and adolescence
Moderators: Olli Kampman (Tampere, Finland) & Bo Söderpalm (Gothenburg, Sweden)
Title to be confirmed
Michael B. Lensing (Oslo, Norway)
ADHD: Adjusting treatment from adolescence to adulthood 
Speaker to be confirmed
Diagnostic criteria in ADHD: adults vs adolescence
Speaker to be confirmed
13.15-14.00 LUNCH 
14.00-14.45 SCNP LECTURE
Moderator: Olli Kampman (Tampere, Finland)
Reward Mechanisms and aversive stimuli revisited: implications for clinical outcome
David Engblom (Sweden)
14.45-15.00 LEG STRETCHING BREAK 
15.00-16.30 PLENARY SESSION
Microbiome: Clinical pharmacology and pharmacological relevance
Moderators: Sophie Erhardt (Stockholm, Sweden) & Gregers Wegener (Aarhus, Denmark)
The microbiome in health and disease
Manimozhiyan Arumugam (Copenhagen, Denmark)
Probiotics ameliorates depression and endocrine diseases
Anders Abildgaard (Aarhus, Denmark)
From probiotics to psychobiotics
Gerard Clarke (Cork, Ireland) 
16.30 CONCLUSION OF THE MEETING

 

 

About SCNP

SCNP (Scandinavian College of Neuropsychopharmacology) is the leading psychopharmacology organisation in the Nordic countries, Sweden, Norway, Denmark, Iceland and Finland.

Its mission is to promote research and education in neuropsychopharmacology. It also provides advice on all aspects of neuro-psychiatric drugs. Through these activities it seeks to advance research thus leading to improved patient care.

The SCNP journal, ‘Acta Neuropsychiatrica’ is becoming an essential journal and grows in importance.

SCNP welcomes membership applications from all who are dedicated to the highest quality research in neuropsychopharmacology.

 

Submit your research to Acta Neuropsychiatrica

Submit papers to Acta Neuropsychiatrica HERE.

Acta Neuropsychiatrica, the official Journal of Scandinavian College of Neuropsychopharmacology, is an international journal focussing on translational neuropsychiatry. It publishes high-quality original research papers and reviews. The Journal’s scope specifically highlights the pathway from discovery to clinical applications, healthcare and global health that can be viewed broadly as the spectrum of work that marks the pathway from discovery to global health. The steps of translation that are within the scope include: 1) fundamental discovery, 2) bench to bedside, 3) clinical trials, 4) translation to clinical guidelines, 5) health policy and usage, and 6) global health. Research covering molecular biology, genetics, pharmacology, imaging and epidemiology is welcome as it contributes to enhancing the field.